Financial Ratios

RAYMED LABS LTD.

NSE : NABSE : 531207ISIN CODE : INE741C01017Industry : Pharmaceuticals & DrugsHouse : Private
BSE2.390 (0 %)
PREV CLOSE ( ) 2.39
OPEN PRICE ( ) 2.39
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 500
TODAY'S LOW / HIGH ( )2.39 2.39
52 WK LOW / HIGH ( ) 2.042.46
NSE
This Company is not listed in NSE
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.40-0.19-0.16-0.13-0.13
   CEPS(Rs)-0.39-0.18-0.15-0.12-0.11
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)-5.40-5.00-4.80-4.64-4.51
   Tax Rate(%)0.000.000.000.000.00
Margin Ratios
   Core EBITDA Margin(%)
   EBIT Margin(%)
   Pre Tax Margin(%)
   PAT Margin (%)
   Cash Profit Margin (%)
Performance Ratios
   ROA(%)-85.07-32.96-27.07-21.34-20.01
   ROE(%)0.000.000.000.000.00
   ROCE(%)0.000.00-94.35-105.49-58.42
   Asset Turnover(x)0.000.000.000.000.00
   Sales/Fixed Asset(x)0.000.000.000.000.00
   Working Capital/Sales(x)0.000.000.000.000.00
Efficiency Ratios
   Fixed Capital/Sales(x)
   Receivable days
   Inventory Days
   Payable days
Valuation Parameters
   PER(x)0.000.000.000.000.00
   PCE(x)-5.27-8.78-6.50-8.34-20.75
   Price/Book(x)-0.38-0.32-0.20-0.21-0.51
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)
   EV/Core EBITDA(x)-5.27-8.78-40.74-48.99-168.68
   EV/EBIT(x)-5.10-8.23-37.38-43.70-55.60
   EV/CE(x)5.602.7410.229.4711.23
   M Cap / Sales
Growth Ratio
   Net Sales Growth(%)
   Core EBITDA Growth(%)-115.31-21.65-27.12-181.5116.59
   EBIT Growth(%)-108.38-19.12-23.60-4.025.51
   PAT Growth(%)-108.32-19.21-23.59-4.035.47
   EPS Growth(%)-108.33-19.18-23.64-4.015.47
Financial Stability Ratios
   Total Debt/Equity(x)0.000.00-1.05-1.02-1.04
   Current Ratio(x)0.060.520.040.040.04
   Quick Ratio(x)0.060.520.040.040.04
   Interest Cover(x)-1123.63-853.75-2548.30-2319.46-2548.29
   Total Debt/Mcap(x)0.000.005.274.872.04

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.